Edition:
India

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

11.88USD
2:29am IST
Change (% chg)

$0.88 (+8.00%)
Prev Close
$11.00
Open
$11.10
Day's High
$12.17
Day's Low
$11.10
Volume
101,128
Avg. Vol
40,377
52-wk High
$17.75
52-wk Low
$8.64

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $206.81
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

09 Nov 2017

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

27 Oct 2017

BRIEF-Tocagen Q2 loss per share $0.56

* Tocagen reports second quarter 2017 financial and business results

10 Aug 2017

BRIEF-Tocagen reports quarterly loss per share $0.56‍​

* Qtrly license revenue $10,000 versus $13,000 Source text: (http://bit.ly/2wuNluv) Further company coverage:

10 Aug 2017

BRIEF-Tocagen receives PRIME designation for Toca 511

* Tocagen receives European Medicines Agency Priority Medicines (PRIME) designation for Toca 511 in high grade Glioma Source text for Eikon: Further company coverage:

24 Jul 2017

Earnings vs. Estimates